氟马替尼治疗初发Ph阳性T细胞急性淋巴细胞白血病1例并文献复习  

A case with philadelphia-positive T-Cell Acute Lymphoblastic Leukemia in the treatment of flumatinib and a review of literature

作　　者：孙艳舫 王海南 吕春颖 任静 杨淑莲 王会朋 SUN Yan-fang;WANG Hai-nan;LV Chun-ying(Langfang Traditional Chinese Medicine Hospital,Langfang 065000,China.)

机构地区：[1]廊坊市中医医院血液病三科,河北廊坊065000

出　　处：《中国处方药》2023年第5期37-39,共3页Journal of China Prescription Drug

摘　　要：T细胞急性淋巴细胞白血病(T-cell acute lymphoblastic leukemias,T-ALL)临床罕见,预后极差。我们报道1例初发Ph阳性T-ALL,应用多药化疗联合国产第2代酪氨酸酶激酶抑制剂(tyrosine-kinase inhibitor,TKI)氟马替尼治疗疗效显著,初次诱导后获完全缓解(CR),5个月时流式微小残留白血病(minimal residual disease,MRD)转阴、BCR-ABLP190评价获主要分子学反应,20个月时,获分子生物学完全缓解(CMR),目前处于口服化疗方案维持治疗中,无移植干预情况下无复发生存期已近24个月。T-cell acute lymphoblastic leukemia(T-ALL)is rare and has a very poor prognosis.We report the case of a newly diagnosed Ph-positive T-ALL patient who received multi-drug chemotherapy in combination with domestic second-generation tyrosine-kinase inhibitor(TKI)flumatinib,which showed significant efficacy and achieved complete remission(CR)after the initial induction.Minimal residual leukemia(MRD)was negative at five months,and BCR-ABLP190 obtained the major molecular reaction.It obtained complete molecular remission(CMR)at 20 months.Up to now,the patient is in the maintenance treatment of oral chemotherapy regimen.The recurrence-free survival is nearly 24 months without hematopoietic stem cell transplantation.

关 键 词：氟马替尼 T细胞急性淋巴细胞白血病 PH阳性 

分 类 号：R733.71[医药卫生—肿瘤]